Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Novavax Inc. (NVAX) rose 98.7% to $8.88 on volume of 168,692,127 shares AEye Inc. (LIDR) rose 115.0% to $2.58 on volume of 156,236,079 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 17.3% to $0.7609 on volume of 123,678,040 s...
A look at the top 10 most actives in the United States Novavax Inc. (NVAX) rose 128.7% to $10.225 on volume of 69,182,168 shares SoundHound AI Inc. (SOUN) rose 23.9% to $5.885 on volume of 25,153,154 shares Greenwave Technology Solutions Inc. (GWAV) fell 31.9% to $0.0476 on volume of 22,3...
2024-05-10 08:00:05 ET Catherine Ramsey Schulte from Robert W. Baird issued a price target of $117.00 for NTRA on 2024-05-10 06:50:00. The adjusted price target was set to $117.00. At the time of the announcement, NTRA was trading at $95.55. The overall price target cons...
2024-05-09 23:28:04 ET Natera, Inc. (NTRA) Q1 2024 Earnings Conference Call May 09, 2024 04:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevich - President, Clinical Diagnostics Alex A...
2024-05-09 17:47:18 ET Gainers: Inseego ( INSG ) +22% . Natera ( NTRA ) +18% . CareDx ( CDNA ) +13% . SoundHound ( SOUN ) +13% . Funko ( FNKO ) +12% . Losers: MacroGenics ( MGNX ) -62% . Progyny ( PGNY...
2024-05-09 16:27:33 ET More on Natera Natera: Capitalizing On The Positive Momentum Of Personalized Medicine Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript Natera upgraded at Bernstein on gross margin trajectory Carpenter Technology, Natera, ethereum pi...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial Highlights Achieved positive cash flow of approximately $3.0 million 1 in the first ...
Expanded EBLIS study with up to 12 years of clinical follow-up across all subtypes of breast cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its pers...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on May 9, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4...
Backed by large clinical validation study with over 650 RhD-negative patients with confirmed outcomes, resulting in 100% sensitivity and >99% specificity Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...